If the company could get full approval from the FDA simply by designing and initiating a new trial and promising to run it in good faith, wouldn't any CEO jump on that opening?
It would be a no-brainer imo... and that's why I don't think it could be that easy. If it was, ency wouldn't be dealing with an approvable letter at this time.
Market Data 
Markets 
AI
